Experienced in Status Epilepticus

Junya Kuroda

Kyoto, JP 
Experienced in Status Epilepticus
Kyoto, JP 
OverviewLocationsClinical Research

Overview

Junya Kuroda practices in Kyoto, Japan. Ms. Kuroda is rated as an Experienced expert by MediFind in the treatment of Status Epilepticus. Her top areas of expertise are Multiple Myeloma, Non-Hodgkin Lymphoma, B-Cell Lymphoma, Bone Marrow Transplant, and Thymectomy.

Her clinical research consists of co-authoring 290 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 2 articles in the study of Status Epilepticus.

Gender
Female

Locations

Kyoto, Japan
Other Locations
Koga, Japan
Japan
Koga, 8113195, Japan
Fukuoka, Japan
Osaka, Japan
Higashi, 8128582, Japan
Kashiwa, 2778564, Japan

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

A Phase 3 Open-Label, Randomized Study of Fixed Duration Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab Versus Venetoclax and Rituximab in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN CLL-322)
A Phase 3 Open-Label, Randomized Study of Fixed Duration Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab Versus Venetoclax and Rituximab in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN CLL-322)
Enrollment Status: Active_not_recruiting
Publish Date: September 02, 2025
Intervention Type: Drug
Study Drugs: Pirtobrutinib, Venetoclax, Rituximab
Study Phase: Phase 3
A Phase 3 Open-Label, Randomized Study of LOXO-305 Versus Investigator Choice of BTK Inhibitor in Patients With Previously Treated BTK Inhibitor Naïve Mantle Cell Lymphoma (BRUIN MCL-321)
A Phase 3 Open-Label, Randomized Study of LOXO-305 Versus Investigator Choice of BTK Inhibitor in Patients With Previously Treated BTK Inhibitor Naïve Mantle Cell Lymphoma (BRUIN MCL-321)
Enrollment Status: Active_not_recruiting
Publish Date: May 28, 2025
Intervention Type: Drug
Study Drugs: LOXO-305, Ibrutinib, Acalabrutinib, Zanubrutinib
Study Phase: Phase 3
View 1 Less Clinical Trial

290 Total Publications

Late-Onset Angioimmunoblastic T-cell Lymphoma During Nivolumab Treatment for Melanoma.
Late-Onset Angioimmunoblastic T-cell Lymphoma During Nivolumab Treatment for Melanoma.
Journal: Cureus
Published: July 29, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ms. Kuroda's expertise for a condition
ConditionClose
    View All 9 Advanced Conditions
    View All 70 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile